GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » ROC (Joel Greenblatt) %

Acer Therapeutics (Acer Therapeutics) ROC (Joel Greenblatt) % : -13,418.75% (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Acer Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -13,418.75%.

The historical rank and industry rank for Acer Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

ACER' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -24688.5   Med: -13574.03   Max: -1045.71
Current: -14853.6

During the past 13 years, Acer Therapeutics's highest ROC (Joel Greenblatt) % was -1045.71%. The lowest was -24688.50%. And the median was -13574.03%.

ACER's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -333.73 vs ACER: -14853.60

Acer Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 11.80% per year.


Acer Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Acer Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics ROC (Joel Greenblatt) % Chart

Acer Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22,385.57 -18,398.15 -14,075.93 -13,072.13 -14,962.92

Acer Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25,232.14 -21,493.33 -13,670.13 -9,571.22 -13,418.75

Competitive Comparison of Acer Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Acer Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acer Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acer Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Acer Therapeutics's ROC (Joel Greenblatt) % falls into.



Acer Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.412 + 0.815) - (5.919 + 2.89 + 0.637)
=-8.219

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 4.601 + 0.598) - (10.438 + 0.182 + 0.63799999999999)
=-6.059

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Acer Therapeutics for the quarter that ended in Jun. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-17.176/( ( (0.202 + max(-8.219, 0)) + (0.054 + max(-6.059, 0)) )/ 2 )
=-17.176/( ( 0.202 + 0.054 )/ 2 )
=-17.176/0.128
=-13,418.75 %

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acer Therapeutics  (OTCPK:ACER) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Acer Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acer Therapeutics (Acer Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Executives
Chris Schelling director, officer: President and Chief Executive C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden officer: Chief Operating Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel officer: Chief Medical Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul officer: Chief People Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis officer: Chief Business Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph officer: Chief Legal Officer and Secy C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp officer: Chief Technology Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin officer: Chief Opp. and Financial Offr C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello director 500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458

Acer Therapeutics (Acer Therapeutics) Headlines

From GuruFocus